Our best-in-class discovery chemistry services are backed by state-of-the-art infrastructure. We handle a wide range of chemistry services across various platforms from our R and D center in Bangalore. The facility houses 300+ fume hoods with all essential instrumentation across 40 + modular labs.
Our facility has high-end equipments such as automated peptide synthesizers, liberty pro peptide synthesizers, microwave machines, combi-flash MPLC systems and oligo synthesizers. Also, our facility has state-of-the-art 3D virtual reality, high-performance computing ICM-Pro (MolSoft) comprehensive modeling platform.
Our analytical infrastructure is quite extensive with equipments such as:
We also have an in-house reagent collection with around 50,000 chemicals available in-house which enables quick-start to projects. Our library synthesis services are supported by equipment such as a 12-Port SPE vacuum manifold, vacuum concentrator and mass-directed purification systems.
In addition to the above, we have a proprietary compound management system, which is a niche server-based system that helps our customers manage inventory and allows smooth integration to biology services.
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.